Phaseline

Targets › SLC11A2

SLC11A2 (Natural resistance-associated macrophage protein 2): drug programs, companies and trials

3 programs from 3 companies in 14 trials: 7 Phase 4, 5 Phase 3, 2 Phase 2; Hematology, Cardiovascular, Oncology; next expected readout Dec 2026.

Proton-coupled metal ion symporter operating with a proton to metal ion stoichiometry of 1:1. Selectively transports various divalent metal cations, in decreasing affinity: Cd(2+) > Fe(2+) > Co(2+), Mn(2+) >> Zn(2+), Ni(2+), VO(2+). (UniProt, P49281)

Open in Phaseline: the race on SLC11A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PharmacosmosFerric Derisomaltose
Iron delivery via carbohydrate complex; replenishes iron stores in iron-deficiency anemia
SLC11A2Phase 3Iron Deficiency, Anaemia in Children; Chronic Heart Failure; Perioperative Anemia; Iron Deficiency Anemia …Apr 2027
Vanderbilt University Medical CenterIntravenous iron
Iron supplementation to restore iron stores
SLC11A2Phase 2POTS - Postural Orthostatic Tachycardia SyndromeDec 2026
Fox Chase Cancer CenterVenofer (iron sucrose)
Iron replacement therapy
SLC11A2Phase 2AnemiaFeb 2027

Conditions

Iron Deficiency Anemia (2) Anemia (1) Iron Deficiency, Anaemia in Children (1) Chronic Heart Failure (1) Perioperative Anemia (1) Hip Fracture (1) Heart Failure With Reduced Ejection Fraction (1) Heart Failure With Preserved Ejection Fraction (1) Heart Failure (1) IDA - Iron Deficiency Anemia (1) Anemia, Iron Deficiency (1) Gynecologic Cancer (1)

Modalities

small molecule (3)

Companies

Fox Chase Cancer Center (1) Pharmacosmos (1) Vanderbilt University Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.